|
Title
|
|
|
|
Evidence of dose variability and dosing below the FDA and EMA recommendations for intravenous colistin (Polymyxin E) use in children and neonates
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| Intravenous colistin (polymyxin E) has renewed interest as a last-line treatment against antimicrobial-resistant Gram-negative bacterial infections, despite limited literature on pediatric prescribing practices. Point-prevalence surveys were used to obtain intravenous colistin prescribing data from 78 children and neonates, showing high variability, and 60.3% received doses below the Food and Drug Administration and the European Medicines Agency recommendations. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
The pediatric infectious disease journal. - Baltimore, Md
|
|
|
Publication
|
|
|
|
Baltimore, Md
:
2020
|
|
|
ISSN
|
|
|
|
0891-3668
|
|
|
DOI
|
|
|
|
10.1097/INF.0000000000002847
|
|
|
Volume/pages
|
|
|
|
39
:11
(2020)
, p. 1032-1034
|
|
|
ISI
|
|
|
|
000577727800025
|
|
|
Pubmed ID
|
|
|
|
32773667
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (open access)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|